HB Fuller has offered to acquire AMS for £715 million in cash, expanding its medical adhesives platform and driving higher-margin growth. The deal widens HB Fuller’s total addressable market to about $95 billion and targets roughly $55 million in run-rate synergies by 2031, financed 100% with a plan to de-leverage post-close. Approval from AMS shareholders and regulators is required, with close anticipated by year-end.
H.B. Fuller reports Q2 results after the close on June 24. Analysts expect EPS of $1.38 on about $923.6 million in revenue, and the company recently raised the dividend by 4.3%. A solid print could prompt a short-term move toward the $65 level as investors weigh growth prospects and cash returns.
H.B. Fuller has made an unsolicited offer to acquire Advanced Medical Solutions, which may enhance Fuller’s healthcare product offerings following a failed previous buyout. This strategic move could bolster Fuller’s market presence in the medical adhesives sector, with potential positive impacts on growth and margins.
J.P. Morgan maintains Underweight rating on FUL, lowering forecast to $50. First-quarter revenue fell 2.7% to $789 million, organic growth up 1.9%. Health segment saw EBITDA drop 25%, signaling ongoing weakness. Adjusted EBITDA expected to grow only 1% in FY2025 amidst market softness. Solar panel business may decline 20% due to oversupply in China.
H.B. Fuller will release Q1 results on March 26. Analysts predict earnings of 50 cents per share, down from 67 cents last year. Revenue for the quarter is projected at $769.11 million, a decline from $810.42 million. The stock recently closed down 1.1% at $53.83. Analysts' ratings on FUL show mixed sentiments, with downgrades impacting outlook.
H.B. Fuller acquires GEM and Medifill in medical adhesives sector. Acquisitions expected to generate €23 million revenue in 2024. Strengthens FUL's position in highly profitable medical adhesive market. Focus on enhancing global Medical Adhesive Technologies division. Purchase price set at €180 million with potential post-synergy benefits.
